Glaukos (GKOS) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

GKOS Glaukos

Watchlist

120.490
-0.020-0.02%

Close Feb 26 16:00 ET

120.490
0.0000.00%

Post 16:05 ET

6.82BMarket Cap-43.50P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Morgan Stanley Maintains Glaukos(GKOS.US) With Sell Rating, Cuts Target Price to $110
Moomoo NewsFeb 26 08:31 ET · Ratings
Glaukos | 10-K: FY2024 Annual Report
SECFeb 25 13:12 ET · Announcements
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Cuts Target Price to $155
Moomoo NewsFeb 25 05:33 ET · Ratings
BTIG Reaffirms Their Buy Rating on Glaukos (GKOS)
TipRanksFeb 25 05:29 ET · Ratings
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today
BenzingaFeb 24 09:45 ET
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery
BenzingaFeb 24 09:12 ET

Comments

Teddy123

Feb 24 06:16

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa

$Glaukos (GKOS.US)$
Revolutionary Eye Treatment Advances: Can Glaukos Transform Keratoconus Care Without Surgery?

Moomoo AI

Jan 21, 2024 08:51

Glaukos' revenue growth is the market's focus due to its unprofitability. The 88% share price gain is solid, not standout. Market sentiment is lukewarm, hinting at potential stronger growth trends. Recent sentiment is positive due to strong share price momentum.

Investors Bid Glaukos (NYSE:GKOS) up US$137m Despite Increasing Losses YoY, Taking One-year Return to 88%

Meltyy

Dec 19, 2023 01:33

PDUFA Update…

Last week’s PDUFAs:
$Arcutis Biotherapeutics (ARQT.US)$ : Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co (MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos (GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co (MRK.US)$ : Approved ...

Meltyy

Dec 4, 2023 01:48

PDUFA Events for December 2023

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics (CRSP.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $OptiNose (OPTN.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $Calliditas Therapeutics (CALT.US)$ $bluebird bio (BLUE.US)$ $Glaukos (GKOS.US)$ $Ionis Pharmaceuticals (IONS.US)$ $Amgen (AMGN.US)$ $Merck & Co (MRK.US)$

Moomoo AI

Nov 3, 2023 06:30

Glaukos' stock carries risk due to losses and high debt, despite cash reserves. The absence of EBIT level profits and free cash flow make sustainability questionable. Investors should proceed with caution.

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

GKOS Glaukos

Trade Overview

Capital Trend

News

Comments

Trending Stocks